Stay up to date on the progress of the pTau217 biomarker assay
In March 2022, we announced a collaboration between Quanterix and Eli Lilly to advance Alzheimer’s Disease diagnosis, monitoring, and treatment. As part of the collaboration, Quanterix received a non-exclusive, world-wide license to Lilly’s proprietary pTau217 antibody technology for near-term use in research use only (RUO) products and services, and future diagnostic applications.
Soon we will be able to offer early access to pTau217. By complete the form, you will:
- Be added to our notification list and can submit RUO samples for analysis in our Accelerator Lab and begin collecting data.
- Remain updated through periodic communications on our progress towards commercialization of this important biomarker.